Peer-reviewedCC BY-NC-NDInternal Medicine
MRI-negative combined central and peripheral demyelination involving a spinal cord with anti-lactosylceramide antibody
Abstract
Combined central and peripheral demyelination (CCPD) is a rare neurological disorder affecting both the central and peripheral nervous systems, and its clinical features have yet to be fully characterized. Conventionally, MRI abnormalities have been used to identify central nervous system involvement in CCPD. We herein describe a patient who developed demyelinating peripheral neuropathy after being diagnosed with MRI-negative myelopathy and thereafter was definitively diagnosed with CCPD. The cerebrospinal fluid test was positive for anti-lactosylceramide antibodies, which are associated with CCPD. This study highlights the need to be aware of MRI-negative CCPD and encourages the active investigation of relevant antibodies to advance both understanding and treatment.
Related
- Systematic Review and Meta-Analysis on Central and/or Peripheral Nervous System Demyelination in Patients Treated With Tumor Necrosis Factor Alpha (TNF-α) Inhibitors
- Demyelination of the central nervous system and peripheral neuropathy associated with sintilimab treatment for lung adenocarcinoma: a case report.
- Autologous Peripheral Blood-Derived Stem Cells Combined with Platelet-Rich Plasma is Associated With Clinical and Radiological Improvement in Anterior Cruciate Ligament Ruptures—Preliminary Clinical and MRI Findings in 47 Consecutive Patients
- Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
BibTeX
@article{ueda2026mrinegative,
title = {{MRI-negative combined central and peripheral demyelination involving a spinal cord with anti-lactosylceramide antibody}},
author = {Tetsuhiro Ueda and Yukiko Tsuji and Maika Yoshida and Yoichi Ohshima and Tatsuro Mutoh and Kazuhide Iwamoto and Tomoyuki Ohara},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7179-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7179-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - MRI-negative combined central and peripheral demyelination involving a spinal cord with anti-lactosylceramide antibody
AU - Tetsuhiro Ueda
AU - Yukiko Tsuji
AU - Maika Yoshida
AU - Yoichi Ohshima
AU - Tatsuro Mutoh
AU - Kazuhide Iwamoto
AU - Tomoyuki Ohara
PY - 2026
DA - 2026/07/18
JO - Internal Medicine
DO - 10.2169/internalmedicine.7179-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7179-26/_article
AB - Combined central and peripheral demyelination (CCPD) is a rare neurological disorder affecting both the central and peripheral nervous systems, and its clinical features have yet to be fully characterized. Conventionally, MRI abnormalities have been used to identify central nervous system involvement in CCPD. We herein describe a patient who developed demyelinating peripheral neuropathy after being diagnosed with MRI-negative myelopathy and thereafter was definitively diagnosed with CCPD. The cerebrospinal fluid test was positive for anti-lactosylceramide antibodies, which are associated with CCPD. This study highlights the need to be aware of MRI-negative CCPD and encourages the active investigation of relevant antibodies to advance both understanding and treatment.
SN - 1349-7235
SN - 0918-2918
ER -